The website features images of dermatological conditions presented across the skin-colour spectrum—aiming to bolster knowledge where many traditional textbooks have failed.
The new drug Litfulo (ritlecitinib) has reached the Canadian market, while baricitinib (Olumiant) is now approved for alopecia areata and in a new higher-strength tablet.